Microsoft's February 2026 Foundry update includes broader platform changes, but the most immediate developer-facing news for VS Code users is an AI Toolkit refresh centered on tool discovery, agent ...
Intervertebral disc degeneration (IVDD) constitutes a major source of chronic low back pain and functional limitation worldwide, substantially impairing physical activity, sports performance, and ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
Microsoft spent $88.7B on capex in fiscal 2025 for AI infrastructure. This exceeded the projected $80B. Analysts set a $631 price target for Microsoft stock. This implies 30% upside from current ...
However, FoxP3 function and the Treg-specific epigenome operate through distinct yet complementary mechanisms (Table 1). Of note, the preservation of the TSDR within the Foxp3 CNS2 enhancer is ...
From the advent of new innovations to shifting care models, healthcare leaders reflect on what words and trends will define the spine surgery field in 2026. The 23 leaders featured in this article are ...
I am a Backend Developer and Software Engineer with a solid background in Artificial Intelligence in academic and professional fields, looking forwa ...
– Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High Complete Response Rate and Favorable Safety Trend – – Novel Construct for Two ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
NervGen Pharma Corp., a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic disorders, today ...
Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results